Skip to main content
. Author manuscript; available in PMC: 2014 Mar 27.
Published in final edited form as: Support Care Cancer. 2013 Oct 5;22(2):461–468. doi: 10.1007/s00520-013-1998-x

Table 1.

Demographic and medical characteristics for the total sample and by ostomy group

Variable Total
(N=141; N (%))
Never had ostomy
(n =98; N (%))
Past ostomy
(n =18; N (%))
Current ostomy
(n =25; N (%))
Age (mean±SD, year) 57.7±13.2 58.4±13.5 61.3±9.3 52.2±13.0
Female gender 59 (41.8) 40 (40.8) 7 (38.9) 12 (48.0)
Education
  Less than a bachelor’s degree 46 (32.6) 31 (31.6) 8 (44.4) 7 (28.0)
  Bachelor’s degree or advanced degree 95 (67.4) 67 (68.4) 10 (55.6) 18 (72.0)
Ethnicity
  Caucasian 117 (83.0) 81 (82.6) 16 (88.9) 20 (80.0)
  African American 11 (7.8) 8 (8.2) 1 (5.6) 2 (8.0)
  Asian 9 (6.4) 5 (5.1) 1 (5.6) 3 (12.0)
  Other 4 (2.8) 4 (4.1) 0 (0.0) 0 (0.0)
Marital status
  Married or cohabiting 121 (85.8) 83 (84.7) 17 (94.4) 21 (84.0)
Tumor site
  Colon 104 (73.8) 85 (86.7) 7 (38.9) 12 (48.0)
  Rectum 37 (26.2) 13 (13.3) 11 (61.1) 13 (52.0)
Disease stage at survey
  I 13 (9.2) 10 (10.2) 2 (11.1) 1 (4.0)
  II/IIA 24 (17.0) 19 (19.4) 1 (5.6) 4 (16.0)
  IIIA 3 (2.1) 2 (2.0) 1 (5.6) 0 (0.0)
  IIIB 22 (15.6) 12 (12.2) 5 (27.8) 5 (20.0)
  IIIC 9 (6.4) 6 (6.1) 1 (5.6) 2 (8.0)
  IV 70 (49.6) 49 (50.0) 8 (44.4) 13 (52.0)
  Currently receiving treatment 56 (39.7) 40 (40.8) 4 (22.2) 12 (48.0)
  Length of time since diagnosis (months) 31.5±23.0 31.7±24.6 36.3±15.1 27.1±20.8
Treatment received
  Surgery 132 (93.6) 89 (90.8) 18 (100.0) 25 (100.0)
  Chemotherapy 106 (75.2) 68 (69.4) 16 (88.9) 22 (88.0)
  Radiation 45 (31.9) 16 (16.3) 14 (77.8) 15 (60.0)
  Colostomy (vs. ileostomy) 13 (9.2) 2 (11.1) 11 (44.0)
  Pelvic surgery 50 (35.5) 17 (17.3) 15 (83.3) 18 (72.0)
  Perforations during surgery 6 (4.3) 3 (3.1) 1 (5.6) 2 (8.0)
  Obstruction during surgery 18 (12.8) 11 (11.2) 3 (16.7) 4 (16.0)
  Post-operative complications 32 (22.7) 16 (16.3) 6 (33.3) 10 (40.0)
  Received Folfox 77 (54.6) 51 (52.0) 9 (50.0) 17 (68.0)
  Received Folfiri 22 (15.6) 17 (17.3) 2 (11.1) 3 (12.0)
  Received Xelox/Xeloda 20 (14.2) 12 (12.2) 5 (27.8) 3 (12.0)